Generic Medicine Info
May be taken with or without food.
Known or suspected ischaemic heart disease (i.e. history of MI, angina pectoris, coronary artery vasospasm, documented silent ischaemia), peripheral vascular disease, severe HTN, uncontrolled mild/moderate HTN, previous CVA or TIA, hemiplegic or basilar migraine. Concomitant use w/ selective serotonin reuptake inhibitors (SSRI), selective norepinephrine reuptake inhibitors (SNRI), ergotamine-containing drugs (e.g. ergotamine tartrate, dihydroergotamine, methysergide), and other 5-HT1 agonists (e.g. triptans).
Special Precautions
Patient w/ history of CV disease, hypercholesterolaemia, DM, hypersensitivity to sulfonamides. Hepatic and severe renal (CrCl ≤30 mL/min) impairment. Childn, elderly. Pregnancy and lactation. Patient Counselling This drug may cause dizziness, somnolence, and visual disturbance, if affected, do not drive or operate machinery. Monitoring Parameters Determine a clear diagnosis of migraine before treatment. Monitor CV status prior to initiation of treatment and periodically thereafter; hepatic and renal function.
Adverse Reactions
Dizziness, somnolence, nausea, vomiting, fatigue; paraesthesia, headache, seizure; angioedema, anaphylactic reactions; visual impairment, tinnitus, palpitation, throat tightness; diarrhoea, dyspepsia, dry mouth, intestinal ischemia, ischaemia; myalgia, bone and chest pain, asthenia. Rarely, coronary vasospasm, tachycardia.
Potentially Fatal: Rarely, MI, disturbance of cardiac rhythm.
Drug Interactions
Increased exposure w/ potent CYP3A4 inhibitors (e.g. ketoconazole).
ATC Classification
N02CC05 - almotriptan ; Belongs to the class of selective serotonin (5HT1) agonists preparations. Used to relieve migraine.
Disclaimer: This information is independently developed by CIMS based on almotriptan from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in